Regina K. Egan

3.7k total citations
8 papers, 259 citations indexed

About

Regina K. Egan is a scholar working on Molecular Biology, Cancer Research and Neurology. According to data from OpenAlex, Regina K. Egan has authored 8 papers receiving a total of 259 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Molecular Biology, 4 papers in Cancer Research and 2 papers in Neurology. Recurrent topics in Regina K. Egan's work include Cancer, Hypoxia, and Metabolism (3 papers), RNA modifications and cancer (2 papers) and Neuroblastoma Research and Treatments (2 papers). Regina K. Egan is often cited by papers focused on Cancer, Hypoxia, and Metabolism (3 papers), RNA modifications and cancer (2 papers) and Neuroblastoma Research and Treatments (2 papers). Regina K. Egan collaborates with scholars based in United States, China and Japan. Regina K. Egan's co-authors include Patricia Greninger, Cyril H. Benes, Ryan J. March, Ayaz Najafov, Ioannis K. Zervantonakis, Adnan K. Mookhtiar, Daniel G. Stover, Ursula A. Matulonis, Junying Yuan and Azeet Narayan and has published in prestigious journals such as Science, Proceedings of the National Academy of Sciences and Nature Communications.

In The Last Decade

Regina K. Egan

8 papers receiving 258 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Regina K. Egan United States	7	171	69	63	56	48	8	259
Lori M. Minassian Canada	3	172 1.0×	159 2.3×	81 1.3×	108 1.9×	66 1.4×	5	354
Aurora Chinnici Italy	6	207 1.2×	26 0.4×	57 0.9×	147 2.6×	70 1.5×	9	330
Kyusam Choi South Korea	7	223 1.3×	45 0.7×	35 0.6×	84 1.5×	77 1.6×	8	330
Song Han United States	5	227 1.3×	36 0.5×	26 0.4×	100 1.8×	54 1.1×	5	316
Anqun Tang China	5	243 1.4×	137 2.0×	25 0.4×	143 2.6×	50 1.0×	6	361
Changran Wei China	7	154 0.9×	101 1.5×	37 0.6×	71 1.3×	41 0.9×	11	276
Yutaro Otsuka Japan	10	203 1.2×	62 0.9×	42 0.7×	132 2.4×	78 1.6×	10	328
Lars A.T. Meijer Netherlands	8	310 1.8×	43 0.6×	30 0.5×	91 1.6×	26 0.5×	8	362
Linda Tran United States	5	169 1.0×	22 0.3×	101 1.6×	149 2.7×	38 0.8×	6	334
Takao Morinaga Japan	9	151 0.9×	62 0.9×	17 0.3×	70 1.3×	29 0.6×	23	229

Countries citing papers authored by Regina K. Egan

Since Specialization

Citations

This map shows the geographic impact of Regina K. Egan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Regina K. Egan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Regina K. Egan more than expected).

Fields of papers citing papers by Regina K. Egan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Regina K. Egan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Regina K. Egan. The network helps show where Regina K. Egan may publish in the future.

Co-authorship network of co-authors of Regina K. Egan

This figure shows the co-authorship network connecting the top 25 collaborators of Regina K. Egan. A scholar is included among the top collaborators of Regina K. Egan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Regina K. Egan. Regina K. Egan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

8 of 8 papers shown

1.

Egan, Regina K., Jianli Ma, Jong Kung, et al.. (2025). Targeting Monounsaturated Fatty Acid Metabolism for Radiosensitization of KRAS Mutant 3D Lung Cancer Models. Molecular Cancer Therapeutics. 24(6). 920–930. 1 indexed citations

2.

Sun, Yang, Lu Hu, Zhipeng Tao, et al.. (2022). Pharmacological blockade of TEAD–YAP reveals its therapeutic limitation in cancer cells. Nature Communications. 13(1). 6744–6744. 70 indexed citations

3.

Cai, Jinyang, Sheeba Jacob, Richard Kurupi, et al.. (2022). High-risk neuroblastoma with NF1 loss of function is targetable using SHP2 inhibition. Cell Reports. 40(4). 111095–111095. 10 indexed citations

4.

Lou, Kevin, Tangpo Yang, Ziyang Zhang, et al.. (2022). IFITM proteins assist cellular uptake of diverse linked chemotypes. Science. 378(6624). 1097–1104. 24 indexed citations

5.

Lochmann, Timothy L., Konstantinos V. Floros, Richard Kurupi, et al.. (2021). Catastrophic ATP loss underlies a metabolic combination therapy tailored for MYCN -amplified neuroblastoma. Proceedings of the National Academy of Sciences. 118(13). 18 indexed citations

6.

Baro, Marta, Azeet Narayan, Wei Cui, et al.. (2018). Oligosaccharyltransferase Inhibition Overcomes Therapeutic Resistance to EGFR Tyrosine Kinase Inhibitors. Cancer Research. 78(17). 5094–5106. 55 indexed citations

7.

Najafov, Ayaz, Ioannis K. Zervantonakis, Adnan K. Mookhtiar, et al.. (2018). BRAF and AXL oncogenes drive RIPK3 expression loss in cancer. PLoS Biology. 16(8). e2005756–e2005756. 68 indexed citations

8.

Yoo, Byunghee, Patricia Greninger, Giovanna T. Stein, et al.. (2018). Potent and selective effect of the mir-10b inhibitor MN-anti-mir10b in human cancer cells of diverse primary disease origin. PLoS ONE. 13(7). e0201046–e0201046. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact